Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | SI | P14410 | 1/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11280915 | 0.89 | SMN1; SMN2 (0.51) | SMN1; SMN2NPSR1LOXL2IDO1HDAC6 | |
| SCHEMBL7409329 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2NPSR1LOXL2IDO1HDAC6 | |
| SCHEMBL334252 | 0.82 | NPC1 (0.61) | SMN1; SMN2NPC1RAB9AGAAPPARA | |
| SCHEMBL8971386 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1LOXL2IDO1NPC1 | |
| SCHEMBL10786161 | 0.81 | IDO1 (0.43) | SMN1; SMN2NPSR1LOXL2IDO1HDAC6 | |
| SCHEMBL5134299 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2NPSR1LOXL2IDO1HDAC6 | |
| SCHEMBL9125270 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2NPSR1LOXL2IDO1HDAC6 | |
| SCHEMBL482340 | 0.81 | LOXL2 (0.61) | SMN1; SMN2NPSR1LOXL2IDO1HDAC6 | |
| SCHEMBL1049510 | 0.81 | SMN1; SMN2 (0.61) | SMN1; SMN2NPSR1LOXL2IDO1HDAC6 | |
| SCHEMBL15088418 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2NPSR1LOXL2IDO1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568399-B1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AGRIMETIS LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| CN-112351984-B | Tetrahydrobenzofuro [2.3-c ] pyridine and beta-carboline compounds for the treatment, alleviation or prevention of conditions associated with Tau aggregate | AC免疫有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230391774-A1 | Novel Compounds | AC IMMUNE SA (CH) | 2023-12-07 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| WO-1992015579-A1 | MULTICYCLIC TERTIARY AMINE POLYAROMATIC SQUALENE SYNTHETASE INHIBITORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| EP-0121871-B1 | PROPIONIC-ACID ESTERS AND THEIR USE IN COMBATING WEEDS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-01-20 | — | — | EP | disclosed |
| CN-85104825-A | The protection farm crop contain benzoxazol base or the amino acid whose pharmaceutical formulation of benzothiazolyl | — | 1986-12-17 | — | — | CN | disclosed |
| EP-0121871-A1 | Propionic-acid esters and their use in combating weeds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-10-17 | — | — | EP | disclosed |
| EP-0018080-B1 | HERBICIDAL COMPOUNDS, THEIR PREPARATION, COMPOSITIONS AND PROCESS FOR THE USE THEREOF | ICI AUSTRALIA LIMITED (AU) | 1984-03-14 | — | — | EP | disclosed |
| US-4314065-A | HERBICIDES | ICI AUSTRALIA LIMITED (AU) | 1982-02-02 | — | — | US | disclosed |
| EP-0000924-B1 | HETEROCYCLIC PHENYL ETHERS AND PROCESS FOR THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-04-29 | — | — | EP | disclosed |
| US-4263440-A | STARTING MATERIALS FOR HERBICIDE PRODUCTION | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-04-21 | — | — | US | disclosed |
| EP-0018080-A1 | Herbicidal compounds, their preparation, compositions and process for the use thereof | ICI AUSTRALIA LIMITED (AU) | 1980-10-29 | — | — | EP | disclosed |
| EP-0000924-A1 | Heterocyclic phenyl ethers and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | SMN1; SMN2 1175/4885NPSR1 80/4885LOXL2 3879/4885 |
| US-20230391774-A1 | Novel Compounds | MAPT, PSEN2, PSEN1 | SMN1; SMN2 497/4885NPSR1 3319/4885LOXL2 3942/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | SMN1; SMN2 1226/4885NPSR1 348/4885LOXL2 3586/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | SMN1; SMN2 479/4885NPSR1 2353/4885LOXL2 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.